New hope for aggressive brain tumors: experimental combo targets first recurrence
Disease control
Not yet recruiting
This early-stage trial tests a new drug, STAR-001, combined with the old blood-pressure medicine spironolactone in about 68 adults whose glioblastoma (a fast-growing brain cancer) has come back after initial treatment. The goal is to see if the combination is safe and can shrink …
Phase: PHASE1, PHASE2 • Sponsor: Starlight Therapeutics Inc. • Aim: Disease control
Last updated May 07, 2026 18:43 UTC